Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Target Price at $4.14
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have received an average rating of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have received an average rating of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price […]
